TETON Study: Inhalation Treatment for IPF

Clinical Trial Title

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (RIN-PF-301)

National Clinical Trial Number:


Contact Information

Kimberly Saulsberry

Clinical Trial Protocol Description:

The purpose of this study is to see how well inhaled treprostinil works in participants with idiopathic pulmonary fibrosis (IPF) and to gather information on how safe it is.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are at least 40 years of age.
  • Have a diagnosis of IPF.
  • If taking pirfenidone or nintedanib, are on a stable and optimized dose for ≥30 days.
  • Are willing and likely to be cooperative with protocol requirements, including attending all study visits.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Xiaoping Wu, MD

Contact Information

Andres Davalos

Kimberly Saulsberry

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more